- Home
- SFNC vs TNGX Comparison
SFNC vs TNGX Comparison
Compare SFNC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SFNC | TNGX |
|---|---|---|
| Founded | 1903 | 2014 |
| Country | United States | United States |
| Employees | N/A | 137 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SFNC | TNGX |
|---|---|---|
| Price | $21.33 | $21.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $22.17 | $21.78 |
| AVG Volume (30 Days) | 843.4K | ★ 2.8M |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $2,607.90 | N/A |
| Revenue Next Year | $4.15 | N/A |
| P/E Ratio | $45.17 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $17.00 | $1.91 |
| 52 Week High | $22.18 | $28.41 |
Technical Indicators
Market Signals| Indicator | SFNC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 45.83 |
| Support Level | $18.65 | $20.76 |
| Resistance Level | $21.63 | $22.01 |
| Average True Range (ATR) | 0.42 | 1.90 |
| MACD | -0.04 | -0.49 |
| Stochastic Oscillator | 64.86 | 33.00 |
Price Performance
Historical ComparisonAbout SFNC Simmons First National Corporation
Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. Its loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.